True, but IMO the only way CYDY defaults is if leronlimab isn’t as advertised. If that’s the case, then us shareholders are doomed in both scenarios. Just to be clear, I fully believe in leronlimab and my investment in CytoDyn. I think the chance of default on such loan is less than combo HIV not being approved (both greater than 99% likely IMO).